glucagon has been researched along with linagliptin in 5 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (linagliptin) | Trials (linagliptin) | Recent Studies (post-2010) (linagliptin) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 598 | 149 | 554 |
| Protein | Taxonomy | glucagon (IC50) | linagliptin (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.3 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.2967 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.0008 | |
| Prolyl endopeptidase FAP | Mus musculus (house mouse) | 0.37 | |
| Prolyl endopeptidase FAP | Homo sapiens (human) | 0.0799 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Aguilar, R; Hehnke, U; Lajara, R; von Eynatten, M; Woerle, HJ | 1 |
| Ahrén, B; Eto, T; Irie, S; Kurose, T; Kuwata, H; Murotani, K; Seino, S; Seino, Y; Shiramoto, M; Yabe, D | 1 |
| Andersen, G; Falk, A; Fischer, A; Forst, T; Heise, T; Kapitza, C; Plum-Mörschel, L; Voswinkel, S; Weber, MM | 1 |
| Dong, EW; Fonseca, VA; Htun, W; Mauvais-Jarvis, F; Wu, H; Wu, M; Zhang, Y | 1 |
3 trial(s) available for glucagon and linagliptin
| Article | Year |
|---|---|
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Epinephrine; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Japan; Linagliptin; Liraglutide; Male; Middle Aged; Norepinephrine | 2017 |
Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Linagliptin; Male; Middle Aged; Postprandial Period; Proinsulin; Treatment Outcome | 2017 |
2 other study(ies) available for glucagon and linagliptin
| Article | Year |
|---|---|
Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonylurea Compounds; Treatment Outcome | 2014 |
Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors.
Topics: Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Humans; Hypoglycemic Agents; Insulin Secretion; Insulin-Secreting Cells; Linagliptin | 2017 |